Cleared for Market · Kai London
FDA and EU Medical Device Cybersecurity for 2026: Threat Models, SBOMs, Security Testing and Submission Evidence
One connected device, two regulators. Can your evidence satisfy the FDA and a notified body at once?
No downloads, no subscriptions, nothing extra to buy: every numbered item in this book is printed in full and completed for a worked organisation, so you can adapt it to your own organisation straight from the page.
Premium Practitioner Edition. A complete working reference, not a quick read: practitioner chapters, a field toolkit of worked case studies, and a reference section with practice questions, checklists, an executive summary and an operating model you can adopt.
One connected device, two regulators. Can your evidence satisfy the FDA and a notified body at once?
Updated for the FDA premarket cybersecurity guidance as reissued in February 2026 and the Quality Management System Regulation in force from 2 February 2026. Under section 524B of the Federal Food, Drug, and Cosmetic Act the FDA can refuse to accept a cyber device submission that lacks a postmarket vulnerability plan, processes giving reasonable assurance of cybersecurity, or a software bill of materials. In the EU a notified body assesses the same device against MDR Annex I GSPR 17.2, 17.4, 18.8 and 23.4(ab), in technical documentation structured by Annexes II and III. This book shows how to build one engineering evidence base and express it natively for each reviewer, without the two files contradicting each other.
Twelve chapters follow a fictional connected ambulatory infusion pump system from security design inputs through pathway and boundary decisions, architecture, threat modelling, secure development, SBOM and provenance, authentication and updates, penetration testing, postmarket disclosure, the eSTAR package, the MDR technical file and traceability with design change control.
Inside you will find:
• Forty-eight completed submission evidence items, each mapped to eSTAR and Annex II
• Thirty-six threat scenarios scored on exploitability and traced to tests and residual risk
• SBOM, VEX and supplier assurance records that answer disclosure-day questions in hours
• Twelve dated lifecycle cases, from design inputs to FDA clearance and notified body review
• Case studies, ten labs, fourteen templates, exercises, sixty questions and a 90-day plan
Every submission evidence item (SE-01 to SE-48) is shown completed, with its FDA reference, EU reference, owner, acceptance criteria and the deficiency reviewers most often raise. Every threat scenario (TS-01 to TS-36) runs from entry point to clinical consequence, controls, verification and submission proof, and every lifecycle case (LC-01 to LC-12) records the decisions taken in each jurisdiction. Chapter 12 prints the consolidated dual-jurisdiction index of all ninety-six items.
Part II is a field toolkit: two case studies, ten hands-on labs, fourteen completed templates, a five-level, ten-dimension maturity model with twenty-nine metrics and a ninety-day implementation plan. Part III adds a standards and regulatory crosswalk, six tabletop exercises, sixty practice questions, thirty failure patterns with recovery steps and a tooling and vendor evaluation guide.
Who it is for: medical device product-security leads, regulatory affairs specialists, clinical risk managers, systems architects and the quality and audit teams who must defend connected devices in both the US and the EU.
Part of the Professional Validation Library by Professor Kai London: practical books that turn standards, technology and regulation into work you can evidence. The print editions include an author's note, a ten-point readiness self-check, an afterword, twelve framework figures, key takeaways for every chapter, a RACI matrix, an eight-dimension quick scorecard mapped to the Part II maturity model, a 90-day plan, a list of abbreviations and a full index.
Professor Kai London